Inhibition of the arachidonic acid cascade by norathyriol via blockade of cyclooxygenase and lipoxygenase activity in neutrophils

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 5, 2004, Pages 507-515

  Hsu, Mei Feng ^b   Lin, Chun Nan ^c   Lu, Min Chi ^d   Wang, Jih Pyang ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Arachidonic acid release; Cyclooxygenase; Lipoxygenase; Neutrophils; Norathyriol; Phospholipase A 2

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CALCIMYCIN; CYCLOOXYGENASE 1 INHIBITOR; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEUKOTRIENE B4; LIPOXYGENASE; NORATHYRIOL; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2; XANTHONE DERIVATIVE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL FREE SYSTEM; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; ENZYME ACTIVATION; FATTY ACID SYNTHESIS; HUMAN; IC 50; LEUKOCYTE ACTIVATION; MAST CELL; METABOLIC CAPACITY; MOUSE; NEUTROPHIL; NONHUMAN; RAT; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION;

ANIMALS; ARACHIDONIC ACID; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; LIPOXYGENASE; MAST CELLS; MICE; NEUTROPHILS; PROSTAGLANDIN D2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; XANTHENES;

EID: 2442657655     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0922-9     Document Type: Article

References (38)

1. Becan TM, Rosebury WS, Mueller SB, Kuchera S, Welch K, Daughterly A, Cornicelli JA (1998) A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis 136:203-216
2. Celotti F, Laufer S (2001) Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 43:429-436
3. 2+-dependent translocation domain with homology to PKC and GAP. Cell 65:1043-1051
4. 2 for activation of the phagocyte NADPH oxidase. J Biol Chem 273:441-445
5. De Gaetano G, Donati MB, Cerletti C (2003) Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol Sci 24:245-252
6. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czemiak PM, Gorry SA, Trzaskos JM (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378:406-409
7. Ford-Hutchinson AW, Gresser M, Young RN (1994) 5-Lipoxygenase. Annu Rev Biochem 63:383-417
8. 2 regulation. J Biol Chem 275:20146-20156
9. Hatley ME, Srinivasan S, Reilly KB, Bolick DT, Hedrick CC (2003) Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J Biol Chem 278:25369-25375
10. 2. J Biol Chem 266:7227-7232
11. Hennan JK, Huang J, Barrett T, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104:820-825
12. Hsu MF, Raung SL, Tsao LT, Lin CN, Wang JP (1997) Examination of the inhibitory effect of norathyriol in formylmethionyl-leucyl-phenylalanine-induced respiratory burst in rat neutrophils. Free Radic Biol Med 23:1035-1045
13. Hsu MF, Lu MC, Tsao LT, Kuan YH, Chen CC, Wang JP (2004) Mechanisms of the influence of magnolol on eicosanoid metabolism in neutrophils. Biochem Pharmacol 67:831-840
14. Hsuanyu Y, Dunford HB (1992) Prostaglandin H synthase kinetics: the effect of substituted phenols on cyclooxygenase activity and the substituent effect on phenolic peroxidatic activity. J Biol Chem 267:17649-17657
15. 2 specific for sn-arachidonic acid. Methods Enzymol 187:216-225
16. Lin CN, Liou SS, Ko FN, Teng CM (1992) γ-Pyrone compounds. II. Synthesis and antiplatelet effects of tetraoxygenated xanthones. J Pharm Sci 81:1109-1112
17. Lin CN, Liou SS, Ko FN, Teng CM (1993) γ-Pyrone compounds. IV. Synthesis and antiplatelet effects of mono- and dioxygenated xanthones and xanthonoxypropanolamine. J Pharm Sci 82:11-16
18. Lin CN, Chung MI, Liou SY, Lee TH, Wang JP (1996) Synthesis and anti-inflammatory effects of xanthone derivatives. J Pharm Pharmacol 48:532-538
19. Liou SS, Shieh WL, Cheng TH, Won SJ, Lin CN (1992) γ-Pyrone compounds as potential anti-cancer drugs. J Pharm Pharmacol 45:791-794
20. Lipsky PE, Brooks P, Crofford LJ, Dubois R, Graham D, Simon LS, van de Putte LB, Abramson SB (2000) Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Int Med 160:913-920
21. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 286:954-959
22. Nelson MJ, Batt DG, Thompson JS, Wright SW (1991) Reduction of the active-site iron by potent inhibitors of lipoxygenase. J Biol Chem 266:8225-8229
23. Otto JC, DeWitt DL, Smith WL (1993) N-glycosylation of prostaglandin endoperoxide synthase-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem 268:18234-18242
24. Pellegrini G, Malandra R, Cell A, Furie BC, Furie B, Lorenzet R (1998) 12-Hydroxyeicosatetraenoic acid upregulates P-selectin-induced tissue factor activity on monocytes. FEBS Lett 441: 463-466
25. Ross R (1999) Atherosclerosis: an inflammatory disease. New Engl J Med 340:115-126
26. Rouzer CA, Samuelsson B (1986) The importance of hydroperoxide activation for the detection and assay of mammalian 5-lipoxygenase. FEBS Lett 204:293-296
27. Smith RJ, Sam LM, Justen JM, Leach KL, Epps DE (1987) Human polymorphonuclear neutrophil activation with arachidonic acid. Br J Pharmacol 91:641-649
28. 2. Biochemistry 32:5935-5940
29. Teng CM, Lin CN, Ko FN, Cheng KL, Huang TF (1989) Novel inhibitory actions on platelet thromboxane and inositol phosphate formation by xanthones and their glycosides. Biochem Pharmacol 38:3791-3795
30. Teng CM, Ko FN, Wang JP, Lin CN, Wu TS, Chen CC, Huang TF (1991) Antihaemostatic and antithrombotic effect of some antiplatelet agents isolated from Chinese herbs. J Pharm Pharmacol 43:667-669
31. Tithof PK, Peters-Golden M, Ganey PE (1998) Distinct phospholipase A2 regulate the release of arachidonic acid for eicosanoid production and superoxide anion generation in neutrophils. J Immunol 160:953-960
32. Vaananen PM, Keenan CM, Grisham MB, Wallace JL (1992) Pharmacological investigation of the role of leukotrienes in the pathogenesis of experiment NSAID gastropathy. Inflammation 16:227-240
33. 2 receptor antagonist, is due to mast cell degranulation. Eur J Pharmacol 161:143-149
34. Wang JP, Hsu MF, Raung SL, Chen CC, Kuo JS, Teng CM (1992) Anti-inflammatory and analgesic effects of magnolol. Naunyn-Schmiedeberg's Arch Pharmacol 346:707-712
35. Wang JP, Raung SL, Lin CN, Teng CM (1994a) Inhibitory effect of norathyriol, a xanthone from Tripterospermum lanceolatum, on cutaneous plasma extravasation. Eur J Pharmacol 251:35-42
36. Wang JP, Ho TF, Lin CN, Teng CM (1994b) Effect of norathyriol, isolated from Tripterospermum lanceolatum, on A23187-induced pleurisy and analgesia in mice. Naunyn-Schmiedeberg's Arch Pharmacol 350:90-95
37. Wang JP, Raung SL, Kuo YH, Teng CM (1995) Daphnoretin-induced respiratory burst in rat neutrophils is, probably, mainly through protein kinase C activation. Eur J Pharmacol 288:341-348
38. Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibein JA, Charleson S, Singer II (1993) 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 178:1935-1946